https://peptide.zone/story/camurus-monthly-semaglutide-depot-phase-2bPeptide Zoneen2026-11-05T04:34:00.000ZCamurus starts Phase 2b trial of monthly semaglutide depot CAM2056 https://peptide.zone/story/pegcetacoplan-c3g-adolescents-proteinuria-76-weeksPeptide Zoneen2026-11-05T04:11:00.000ZPegcetacoplan C3G data show proteinuria cut holds at 76 weeks in adolescents https://peptide.zone/story/wegovy-pill-market-share-novo-outlookPeptide Zoneen2026-11-05T03:37:00.000ZWegovy pill market share holds near 80 percent as Novo raises outlook https://peptide.zone/story/glp-1-dose-hacking-christmas-gpsPeptide Zoneen2026-11-05T03:05:00.000ZGLP 1 dose hacking for Christmas draws caution from UK GPs https://peptide.zone/story/mounjaro-needle-disposal-coventry-recyclingPeptide Zoneen2026-11-04T04:41:00.000ZMounjaro needle disposal warning follows sharps found in Coventry recycling https://peptide.zone/story/fda-peptide-safety-risks-ghrp-ipamorelinPeptide Zoneen2026-11-04T04:21:00.000ZFDA list of compounded peptide safety risks cites GHRP 2 and ipamorelin deaths https://peptide.zone/story/novo-nordisk-q3-results-wegovy-pillPeptide Zoneen2026-11-04T03:37:00.000ZNovo Nordisk Q3 results hinge on Wegovy pill as analysts eye a narrower decline https://peptide.zone/story/uk-watchdog-bans-weight-loss-pill-adsPeptide Zoneen2026-11-04T03:18:00.000ZUK watchdog bans four weight loss pill ads that never named the drug